As part of a €5bn investment by 2025, the Free State of Bavaria will kick off two ambitious digital medicine projects next year, government officials said at the Forum Science & Health.
At the opening ceremony for R&D, training and production buildings at Roche Penzberg, the Pharma giant said that Foundation Medicine (FMI) will establish a digital oncology service at the site offering oncologists across Europe decision support in personalised medicine.
Belgian diagnostics company Biocartis Group NV and Singpore’s A*STAR ETPL have kicked off development of a multimodal breast cancer assay designed to guide therapy selection in personalised medicine.
Small molecule cancer drug developer 4SC AG (Planegg-Martinsried, Germany) has completed a capital increase fueling development of its clinical programmes for resminostat, 4SC-202 and 4SC-208
German biotech company Biontech AG has published positive clinical results for its individualised cancer vaccine Ivac mutanome in patients with late-stage melanoma.
Venture capitalist Seventure Partners announced that it has participated in a US$13m financing of Japanese biotech company Anaeropharma Science. The investment is made from Seventure’s Health for Life Capital investment vehicle.
Last December, Noxxon Pharma AG signed an agreement with Merck & Co./MSD to evaluate the synergistic potential of NOXA1/2 and pembrolizumab immune cancer therapy. Now, the companies have kicked off a Phase I/II study in patients with pancreatic and colorectal cancer.
British pharma giant GlaxoSmithKline has secured access to Ex Scientia Ltd (Exscientia)’s artificial intelligence (AI)-driven drug discovery platform.
![Follicular lymphoma is the most common type of slow-growing blood cancer. [Credit: E. Oricchio et al., Science Translational Medicine (2017)]](https://european-biotechnology.com/wp-content/uploads/2024/04/FL_oricchio1HR-180x180.jpg "FL_oricchio1HR.jpg")
Swiss researchers have found a way to prevent the multiple disease relapses after responses to follicular lymphoma therapy.
Genome editing specialist Cellectis has kicked off clinical tests in the US for the very first of-the-shelf CAR-T cell therapy in acute myeloid leukaemia.